Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenomics: Elizabeth Floegel, Neil Gunn, Tony Zook

NeoGenomics has appointed Elizabeth Floegel, Neil Gunn, and Tony Zook to its board of directors. Floegel, chief information and digital officer of Numotion, will join the board's audit and finance as well as its compliance committee. Gunn, former CEO of IDbyDNA, will be a member of the culture and compensation and of the nominating and corporate governance committee. Zook, former CEO of Innocoll Pharmaceuticals, will serve on the audit and finance and the culture and compensation committee.

Prior to Numotion, Floegel was the global VP of business technology at Allergan (now part of Abbvie). Earlier roles included heading commercial and digital technology for Regeneron Pharmaceuticals and serving as global VP of commercial technology for Baxter Healthcare. Before joining IDbyDNA, Gunn was president of Roche Sequencing Solutions and head of global business for Roche Molecular Diagnostics His earlier roles include VP of commercial operations for CaridianBCT and VP of commercial operations - Americas for Novartis Diagnostics. Prior to serving as CEO of Innocoll Pharmaceuticals, Zook was executive VP of commercial operations at AstraZeneca after having held various other positions in the company, including CEO of North America and VP of sales.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.